
Zynex Inc (ZYXI) Stock Forecast & Price Target
Zynex Inc (ZYXI) Analyst Ratings
Bulls say
Zynex Inc, which specializes in the manufacturing and marketing of medical devices for pain management and rehabilitation, experienced a significant growth in orders, achieving a 16% year-over-year increase in FY2024. The company is focused on enhancing revenue per sales representative with a goal of reaching $1 million, while management has reported positive clinical study results for its laser-based system, positioning it as superior to current alternatives in the market. Additionally, the anticipated expense reductions and potential resolution of payer issues could lead to substantial savings and growth opportunities, further solidifying Zynex's favorable outlook in the medical device industry.
Bears say
Zynex Inc. has experienced significant financial challenges, with projected Q1 2025 sales indicating a decline of 37% year-over-year and 35% sequentially, reflecting ongoing struggles within its Electrotherapy and Pain Management Products segment. The company reported a total revenue of $46.0 million in Q4 2024, which marked a 3% year-over-year decline and fell short of expectations, with device sales down 9% year-over-year. Furthermore, Zynex’s guidance points to a sharp reduction in anticipated sales for 2025, now forecasted at $140 million compared to the previous estimate of $241 million, alongside a projected EPS loss of $0.50, emphasizing a lack of operational visibility and underlying business headwinds.
This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.
Zynex Inc (ZYXI) Analyst Forecast & Price Prediction
Start investing in Zynex Inc (ZYXI)
Order type
Buy in
Order amount
Est. shares
0 shares